Hemogenyx Pharmaceuticals annual operating cash flow
2020
2021
2022
2023
2024
2025
Hemogenyx Pharmaceuticals Operating Cash Flow Growth & History (HEMO)
Hemogenyx Pharmaceuticals's operating cash flow was −£3.4M for fiscal 2025.
View full Hemogenyx Pharmaceuticals company overviewHemogenyx Pharmaceuticals annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£3.4M | £692,067 | — |
| 2024 | 2024-12-31 | −£4.1M | £2.0M | — |
| 2023 | 2023-12-31 | −£6.1M | −£3.2M | — |
| 2022 | 2022-12-31 | −£2.9M | −£283,306 | — |
| 2021 | 2021-12-31 | −£2.6M | −£828,894 | — |
| 2020 | 2020-12-31 | −£1.8M | — | — |
Hemogenyx Pharmaceuticals operating cash flow trends
Over the last five fiscal years, Hemogenyx Pharmaceuticals's operating cash flow decreased from −£1.8M to −£3.4M, a change of −£1.6M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company official filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hemogenyx Pharmaceuticals source filings ↗Community posts
Hemogenyx loss widens on non-cash options charge despite lower underlying spending
Hemogenyx Pharmaceuticals ($HEMO) reported a first-half pretax loss of £6.56 million, widening from £5.01 million. Reported operating costs increased to £6.48 million, but the company attributed most of the rise to a £5.54 million non-cash ...
